Wang et al. described the antitumor potential of a dual inhibitor of GLUT1 and p-EGFR that simultaneously interferes with cancer cell metabolism and driver gene activation for the treatment of different cancer types [41]. The gene discussed is SLC2A1; the disease is cancer.